Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD)
Stock · NASDAQ · Health Care
$4.16as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$0.553838
Industry
Biotechnology: Pharmaceutical Preparations
About GLMD
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3
- Website
- galmedpharma.com
Fundamentals
- 1-day range
- $0.51$0.531
- Market cap
- $4.50M
- P/E (trailing)
- —
- P/E (forward)
- -0.51
- EPS (trailing)
- $-2.06
- Dividend yield
- —
- Beta
- 0.68
- Avg. volume
- 753.4K
52-week range
$0.411$1.65
Galmed Pharmaceuticals Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- GLMDGalmed Pharmaceuticals Ltd. Ordinary Shares$4.16▼ 3.27%Market cap $4.50MP/E —$0.411$1.65
- ZSTKZeroStack Corp. Common Stock$5.51▼ 6.29%Market cap $4.21MP/E —$1.32$47
- INMInMed Pharmaceuticals Inc. Common Shares$1.43▼ 0.35%Market cap $4.09MP/E —$0.575$2.5
- APVOAptevo Therapeutics Inc. Common Stock$2.36▼ 2.48%Market cap $4.92MP/E 0.00$2.3$48.78
- ERNAErnexa Therapeutics Inc. Common Stock$4.57▼ 4.99%Market cap $4.02MP/E —$3.18$71.5
- REVBRevelation Biosciences Inc. Common Stock$1.05▲ 1.94%Market cap $3.99MP/E 0.04$0.875$11.6
- RDHLRedhill Biopharma Ltd. American Depositary Shares$0.6899▲ 9.51%Market cap $3.95MP/E —$0.57$2.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GLMD Galmed Pharmaceuticals Ltd. Ordinary Shares | $4.50M | — | $4.16 | ▼ 3.27% | $0.411$1.65 |
| ZSTK ZeroStack Corp. Common Stock | $4.21M | — | $5.51 | ▼ 6.29% | $1.32$47 |
| INM InMed Pharmaceuticals Inc. Common Shares | $4.09M | — | $1.43 | ▼ 0.35% | $0.575$2.5 |
| APVO Aptevo Therapeutics Inc. Common Stock | $4.92M | 0.00 | $2.36 | ▼ 2.48% | $2.3$48.78 |
| ERNA Ernexa Therapeutics Inc. Common Stock | $4.02M | — | $4.57 | ▼ 4.99% | $3.18$71.5 |
| REVB Revelation Biosciences Inc. Common Stock | $3.99M | 0.04 | $1.05 | ▲ 1.94% | $0.875$11.6 |
| RDHL Redhill Biopharma Ltd. American Depositary Shares | $3.95M | — | $0.6899 | ▲ 9.51% | $0.57$2.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Galmed Pharma’s Subsidiary Colospan Completes Feasibility Study Supporting Development Of Intraoperative Colon Tissue Quality Assessment PlatformBenzinga · 8/19/2026
- Galmed Pharmaceuticals Announces Results From Pre-Clinical Study Of Combination Of Aramchol And Xtandi For Prostatic Cancer; New Data Demonstrated That A Combination Of Aramchol With Enzalutamide Resulted In Three- To Four-Fold Increase In Cell Death Compared With Enzalutamide As A Single AgentBenzinga · 8/17/2026
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 8/3/2026
See the full, filterable feed with live charts on the MarketWall dashboard.